NYSE:RMD

ResMed - RMD Stock Forecast, Price & News

$232.90

+3.56 (+1.55%)

(As of 12/2/2022 12:00 AM ET)

Add

Compare

Today's Range: $227.50
▼
$234.37
50-Day Range: $208.94
▼
$233.97
52-Week Range: $189.40
▼
$268.77

Volume: 368,572 shs
Average Volume: 426,333 shs
Market Capitalization: $34.12 billion

P/E Ratio: 43.53
Dividend Yield: 0.76%
Price Target: $267.00

ResMed MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.60 Rating Score
Upside/Downside: 14.6% Upside
$267.00 Price Target
Short Interest: Healthy
0.74% of Float Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: -1.04
Upright™ Environmental Score
News Sentiment: 0.85
Based on 2 Articles This Week
Insider Trading: Selling Shares
$16.85 M Sold Last Quarter
Proj. Earnings Growth: 12.65%
From $6.48 to $7.30 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.00 out of 5 stars

Medical Sector

12th out of 1,034 stocks

Surgical & Medical Instruments Industry

1st out of 104 stocks

3.3

Analyst's Opinion

Consensus Rating
ResMed has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 6 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $267.00, ResMed has a forecasted upside of 14.6% from its current price of $232.90.
Amount of Analyst Coverage
ResMed has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
0.74% of the float of ResMed has been sold short.
Short Interest Ratio / Days to Cover
ResMed has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in ResMed has recently decreased by 18.32%, indicating that investor sentiment is improving significantly.

1.7

Dividend Strength

Dividend Yield
ResMed has a dividend yield of 0.76%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
ResMed has only been increasing its dividend for 2 years.
Dividend Coverage
The dividend payout ratio of ResMed is 32.90%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, ResMed will have a dividend payout ratio of 24.11% next year. This indicates that ResMed will be able to sustain or increase its dividend.

3.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
ResMed has received a 50.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Personal health record software" and "Medical ventilators" products. See details.
Environmental Sustainability
The Environmental Impact score for ResMed is -1.04.

2.1

News and Social Media Coverage

News Sentiment
ResMed has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.31 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for ResMed this week, compared to 5 articles on an average week.
Search Interest
Only 2 people have searched for RMD on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
Only 8 people have added ResMed to their MarketBeat watchlist in the last 30 days. This is a decrease of -27% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ResMed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,853,023.00 in company stock.
Percentage Held by Insiders
Only 1.39% of the stock of ResMed is held by insiders.
Percentage Held by Institutions
65.50% of the stock of ResMed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for ResMed are expected to grow by 12.65% in the coming year, from $6.48 to $7.30 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ResMed is 43.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 121.83.
Price to Earnings Ratio vs. Sector
The P/E ratio of ResMed is 43.53, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 94.93.
Price to Earnings Growth Ratio
ResMed has a PEG Ratio of 1.50. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
ResMed has a P/B Ratio of 9.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ResMed (NYSE:RMD) Stock

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Receive RMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.

RMD Stock News Headlines

November 29, 2022 | americanbankingnews.com

ResMed Inc. (NYSE:RMD) Receives $266.50 Average Price Target from Analysts

November 29, 2022 | americanbankingnews.com

Head to Head Survey: Femasys (NASDAQ:FEMY) vs. ResMed (NYSE:RMD)

November 22, 2022 | finance.yahoo.com

ResMed Completes Acquisition of MEDIFOX DAN, a German Leader in Out-of-Hospital Care Management Software Solutions

November 10, 2022 | finance.yahoo.com

Here's Why Shareholders Will Not Be Complaining About ResMed Inc.'s (NYSE:RMD) CEO Pay Packet

October 27, 2022 | finance.yahoo.com

ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2023

October 17, 2022 | fool.com.au

2 classic healthcare ASX shares priced to buy now: expert - The Motley Fool Australia

October 17, 2022 | globenewswire.com

CPAP Devices Market Size is projected to reach USD 5254.51 million by 2030, growing at a CAGR of 7.4%: Straits Research - GlobeNewswire

October 14, 2022 | fool.com.au

What's the outlook for ASX healthcare shares in Q2? - The Motley Fool Australia

October 14, 2022 | benzinga.com

ResMed to Report First Quarter Fiscal 2023 Earnings on October 27, 2022 - ResMed (NYSE:RMD) - Benzinga

October 13, 2022 | finance.yahoo.com

ResMed to Report First Quarter Fiscal 2023 Earnings on October 27, 2022

October 12, 2022 | globenewswire.com

Sleep Apnea Devices Market Size to Surpass US$ 12.86 Billion by 2030 - Growth Plus Reports - GlobeNewswire

October 7, 2022 | nytimes.com

How a Hasidic Wedding in the UAE Went Viral on Instagram - The New York Times

September 26, 2022 | finance.yahoo.com

ResMed (RMD) Gains on Product Uptake Even as Expenses Rise

September 25, 2022 | fool.com.au

Not all ASX 200 shares are getting hammered today. Here are some winners - The Motley Fool Australia

September 25, 2022 | fool.com.au

Experts names the blue chip ASX 200 shares to buy - The Motley Fool Australia

September 22, 2022 | benzinga.com

Hopeful Golden Cross Forms On ResMed's Chart - ResMed (NYSE:RMD) - Benzinga

September 21, 2022 | fool.com.au

Experts name 2 outstanding ASX 200 shares to buy right now - The Motley Fool Australia

September 15, 2022 | finance.yahoo.com

Insights on the Respiratory Devices Global Market to 2028 - Featuring Philips Healthcare, ResMed, Medtronic and Masimo Among Others - Yahoo Finance

September 9, 2022 | globenewswire.com

Connected Health and Wellness Solutions Global Market Report 2022 - GlobeNewswire

September 6, 2022 | benzinga.com

Resmed Inc. (RMD) – ResMed Announces Participation in the 20th Annual Morgan Stanley Global Healthcare Conference - Benzinga

September 6, 2022 | nasdaq.com

A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD) - Nasdaq

September 4, 2022 | globenewswire.com

Over 480 Million People Estimated to Have COPD, World's - GlobeNewswire

September 4, 2022 | benzinga.com

Resmed Inc. (RMD) – Over 480 Million People Estimated to Have COPD, World's Third Deadliest Disease, ResM - Benzinga

August 31, 2022 | fool.com

ResMed (NYSE: RMD)

August 31, 2022 | nasdaq.com

Reasons Why You Should Retain ResMed (RMD) Stock For Now - Nasdaq

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive RMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.

RMD Company Calendar

Ex-Dividend for 9/22 Dividend: 8/17/2022
Dividend Payable: 9/22/2022
Last Earnings: 10/27/2022
Ex-Dividend for 12/15 Dividend: 11/09/2022
Today: 12/04/2022
Dividend Payable: 12/15/2022
Next Earnings (Estimated): 1/26/2023
Fiscal Year End: 6/30/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Surgical & medical instruments
Sub-Industry: Health Care Equipment
Sector: Medical
Current Symbol: NYSE:RMD
CUSIP: 76115210
CIK: 943819
Web: www.resmed.com
Phone: (858) 836-5000
Fax: 858-836-5501
Employees: 8,160
Year Founded: 1989

Price Target and Rating

Average Stock Price Forecast: $267.00
High Stock Price Forecast: $280.00
Low Stock Price Forecast: $245.00
Forecasted Upside/Downside: +14.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.60
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): $5.35
Trailing P/E Ratio: 43.53
Forward P/E Ratio: 35.94
P/E Growth: 1.5
Net Income: $779.44 million
Net Margins: 21.70%
Pretax Margin: 26.58%
Return on Equity: 25.75%
Return on Assets: 17.09%

Debt

Debt-to-Equity Ratio: 0.23
Current Ratio: 2.94
Quick Ratio: 1.69

Sales & Book Value

Annual Sales: $3.58 billion
Price / Sales: 9.53
Cash Flow: $7.14 per share
Price / Cash Flow: 32.61
Book Value: $23.43 per share
Price / Book: 9.94

Miscellaneous

Outstanding Shares: 146,480,000
Free Float: 144,448,000
Market Cap: $34.12 billion
Optionable: Optionable
Beta: 0.47

Social Links

Key Executives

Dr. Peter C. Farrell A.M. (Age 80)
AM, B.E., BE (Hons), Ph.D., ScD, Founder & Non-Exec. Chairman
Comp: $430.56k

Mr. Michael J. Farrell BE (Age 50)
MBA, SM, CEO & Director
Comp: $2.66M

Mr. Robert A. Douglas (Age 62)
Pres & COO
Comp: $1.82M

Mr. Brett A. Sandercock (Age 55)
Chief Financial Officer
Comp: $891.39k

Mr. David B. Pendarvis (Age 63)
Chief Admin. Officer, Global Gen. Counsel & Corp. Sec.
Comp: $1.11M

Mr. Kaushik Ghoshal (Age 54)
Pres of SaaS Bus.
Comp: $1.11M

Ms. Urvashi Tyagi
Chief Technology Officer

Ms. Constance C. Bienfait
Director of Investor Relations

Ms. Amy Wakeham
VP of Investor Relations & Corp. Communications

Ms. Vered Keisar
Chief People Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RMD Stock - Frequently Asked Questions

Should I buy or sell ResMed stock right now?: 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last twelve months. There are currently 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RMD shares.
View RMD analyst ratings or view top-rated stocks.
What is ResMed's stock price forecast for 2023?: 10 equities research analysts have issued 12 month target prices for ResMed's stock. Their RMD share price forecasts range from $245.00 to $280.00. On average, they anticipate the company's share price to reach $267.00 in the next twelve months. This suggests a possible upside of 14.6% from the stock's current price.
View analysts price targets for RMD or view top-rated stocks among Wall Street analysts.
How have RMD shares performed in 2022?: ResMed's stock was trading at $260.48 on January 1st, 2022. Since then, RMD stock has decreased by 10.6% and is now trading at $232.90.
View the best growth stocks for 2022 here.
When is ResMed's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, January 26th 2023.
View our RMD earnings forecast.
How were ResMed's earnings last quarter?: ResMed Inc. (NYSE:RMD) posted its quarterly earnings results on Thursday, October, 27th. The medical equipment provider reported $1.51 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.51. The medical equipment provider earned $950.30 million during the quarter, compared to analysts' expectations of $946.07 million. ResMed had a net margin of 21.70% and a trailing twelve-month return on equity of 25.75%. The firm's quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.51 EPS.
Read the conference call transcript.
How often does ResMed pay dividends? What is the dividend yield for ResMed?: ResMed declared a quarterly dividend on Thursday, October 27th. Shareholders of record on Thursday, November 10th will be paid a dividend of $0.44 per share on Thursday, December 15th. This represents a $1.76 dividend on an annualized basis and a yield of 0.76%. The ex-dividend date is Wednesday, November 9th.
Read our dividend analysis for RMD.
Is ResMed a good dividend stock?: ResMed (NYSE:RMD) pays an annual dividend of $1.76 per share and currently has a dividend yield of 0.76%. The company has been increasing its dividend for 2 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 32.90%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RMD will have a dividend payout ratio of 24.11% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RMD.

What is Mick Farrell's approval rating as ResMed's CEO?: 284 employees have rated ResMed Chief Executive Officer Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among the company's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of ResMed own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).
What is ResMed's stock symbol?: ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."
Who are ResMed's major shareholders?: ResMed's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.10%), BlackRock Inc. (9.12%), State Street Corp (4.41%), WCM Investment Management LLC (3.97%), Ownership Capital B.V. (1.01%) and Bank of New York Mellon Corp (0.87%). Insiders that own company stock include Brett Sandercock, Carol Burt, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Lucile Blaise, Michael J Farrell, Peter C Farrell, Rajwant Sodhi, Robert Andrew Douglas and Ronald R Taylor.
View institutional ownership trends.
How do I buy shares of ResMed?: Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is ResMed's stock price today?: One share of RMD stock can currently be purchased for approximately $232.90.
How much money does ResMed make?: ResMed (NYSE:RMD) has a market capitalization of $34.12 billion and generates $3.58 billion in revenue each year. The medical equipment provider earns $779.44 million in net income (profit) each year or $5.35 on an earnings per share basis.
How many employees does ResMed have?: The company employs 8,160 workers across the globe.
How can I contact ResMed?: ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The official website for the company is www.resmed.com. The medical equipment provider can be reached via phone at (858) 836-5000, via email at investorrelations@resmed.com, or via fax at 858-836-5501.

This page (NYSE:RMD) was last updated on 12/4/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial